Cabaletta Bio Inc (CABA) Stock: Assessing the Risk and Reward

3d ago, source: newsheater

In summary, Cabaletta Bio Inc (CABA) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note ...

Takeda ditches industry trade group BIO following exits by WuXi AppTec, Pfizer and UCB

2d ago, source: FiercePharma

Joining a list that recently includes Pfizer, UCB and WuXi AppTec, Takeda Pharmaceuticals is the latest drugmaker to pull out ...

Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program

3d ago, source:

Under the terms of the contract, Applied DNA will supply Linea™ DNA IVT templates to HDT Bio for use in conjunction with its ...

Belite Bio Announces $25 Million Registered Direct Offering

2d ago, source:

The gross proceeds to the Company from the offering are expected to be approximately $25 million (before any warrant exercise), before deducting the expenses payable by the Company. The Company ...

Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced ...

9d ago, source: The Bakersfield Californian

HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi ...

FcRn Inhibitor Market is Predicted to Grow Rapidly During the Study Period (2020–2034) | DelveInsight

12d ago, source:

As per DelveInsight’s analysis, the FcRn inhibitor market is anticipated to grow at a significant CAGR by 2034. Leading FcRn inhibitor companies such as Johnson & Johnson, Immunovant, and others are ...